Apellis FY2023 revenue $396.6M, SYFOVRE drives 160k+ doses; net loss $528.6M

Apellis Pharmaceuticals, Inc.

2023-FY EPS reported -$4.45 revenue$396,591,000

Full year 2023 total revenue $396.6M (vs $75.4M in 2022); SYFOVRE $275.2M, EMPAVELI $91.0M.
SYFOVRE: over 160,000 commercial and sample doses distributed in 2023; Q4 net revenue $114.3M.
Net loss $528.6M for 2023 (vs $652.2M in 2022); cash $351.2M as of Dec 31, 2023.
Entered agreements to unwind ~80% of capped calls on convertible notes due 2026; expects ~$100M proceeds.
G&A expenses rose to $500.8M in 2023 (vs $277.2M in 2022) on SYFOVRE commercial launch costs.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Apellis Pharmaceuticals, Inc. reported the fiscal year ended December 31, 2023 results: revenue $396.6 million.

Period: the fiscal year ended December 31, 2023
Revenue: $396.6 million
Result: reported results

Exact text from the filing

For the full year 2023, total revenue was $396.6 million

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Apellis Pharmaceuticals, Inc. reported the fourth quarter ended December 31, 2023 results: revenue $146.4 million.

Period: the fourth quarter ended December 31, 2023
Revenue: $146.4 million
Result: reported results

Exact text from the filing

Total revenue was $146.4 million for the fourth quarter of 2023

View on SEC.gov

709 earnings releases filed in the last 30 days. Browse all earnings releases →

Apellis Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-047073

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.